Immix Biopharma (IMMX) Cash from Operations (2021 - 2026)

Immix Biopharma has disclosed Cash from Operations across 6 years of filings, most recently posting 9827193.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 9827193.0, down 483.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 32072357.0 (down 157.54% YoY), and the FY2025 annual result was 23930304.0, down 63.96% from the prior year.
• Cash from Operations came in at 9827193.0 for Q1 2026 at Immix Biopharma, up from 11029607.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 547066.0 in Q2 2022 to a low of 11029607.0 in Q4 2025.
• The 5-year median for Cash from Operations is 3515346.0 (2023), against an average of 3948961.18.
• Across the five-year window, Cash from Operations slumped 2781.24% in 2022 and surged 55.97% in 2025, its largest moves.
• Immix Biopharma's Cash from Operations stood at 3903926.0 in 2022, then jumped by 31.42% to 2677437.0 in 2023, then surged by 44.87% to 1476198.0 in 2024, then sank by 647.16% to 11029607.0 in 2025, then advanced by 10.9% to 9827193.0 in 2026.
• The last three Cash from Operations figures came in at 9827193.0 (Q1 2026), 11029607.0 (Q4 2025), and 5905776.0 (Q3 2025), per Business Quant data.